stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs HUTCHMED (China) Limited Sponsored ADR (HCM)
- Amylyx Pharmaceuticals, Inc. AMLX 29.30 +6.08%
- HUTCHMED (China) Limited Sponsored ADR HCM 15.12 +6.48%
Amylyx Pharmaceuticals, Inc. and HUTCHMED (China) Limited Sponsored ADR are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.5B — 1.4× the size. HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against −77.1%. Amylyx Pharmaceuticals, Inc. has the higher net margin (0.00% vs −23.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, HUTCHMED (China) Limited Sponsored ADR leads on 7 and Amylyx Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | AMLX | HCM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 44.40% | 53.51% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | (23.63%) | (2.31%) |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (74.73%) | 0.00% | (0.80%) |
| Return on assets | (66.25%) | 0.00% | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack